Is Buspirone (Buspar) an Antipsychotic?
No, buspirone is not an antipsychotic medication—it is classified as an anxiolytic (anti-anxiety agent) that is structurally and pharmacologically unrelated to benzodiazepines, barbiturates, or antipsychotic drugs. 1
Drug Classification and Mechanism
Buspirone is FDA-approved specifically as an antianxiety agent, not as an antipsychotic. 1
The FDA drug label explicitly states that buspirone "has no established antipsychotic activity" and "should not be employed in lieu of appropriate antipsychotic treatment." 1
Its mechanism involves high affinity for serotonin (5-HT1A) receptors and moderate affinity for brain D2-dopamine receptors, but it lacks significant affinity for benzodiazepine receptors and does not affect GABA binding. 1
Why the Confusion Exists
Buspirone does interact with dopamine receptors (D2, D3, D4), which are also targets of antipsychotic medications, leading to some mechanistic overlap. 2, 3
However, despite acting as an antagonist at presynaptic dopamine receptors, buspirone failed to produce antipsychotic effects and instead resulted in increased dopaminergic metabolites—the opposite of what typical antipsychotics achieve. 2
Research from the 1980s definitively concluded that buspirone "cannot be considered a typical neuroleptic agent" based on its qualitative and quantitative differences from haloperidol and its lack of cataleptogenic properties. 4
Critical Safety Concern: Buspirone Can Worsen Psychosis
The FDA warns that buspirone should not be used as a substitute for antipsychotic treatment, and there is documented evidence that it can worsen psychotic symptoms. 1
A 2023 case report documented buspirone-induced worsening of psychosis in a patient with schizoaffective disorder, with symptoms including increased aggression, paranoia, and odd behaviors on two separate trials. 2
The FDA label specifically warns about serotonin syndrome risk when buspirone is combined with antipsychotics or other dopamine antagonists. 1
Potential Adjunctive Role (Not as Monotherapy)
One randomized controlled trial (2019) showed that co-treatment with buspirone plus atypical antipsychotics improved cognitive deficits in chronic schizophrenia compared to antipsychotics alone, but this was as an adjunct, never as monotherapy. 5
This suggests buspirone may have a limited role as an add-on treatment for specific symptoms (anxiety, cognitive deficits) in patients already stabilized on antipsychotics, but it has no role as primary antipsychotic therapy. 5
Clinical Bottom Line
Buspirone is an anxiolytic medication with no antipsychotic properties. It should never be used to treat psychotic symptoms, and clinicians must be aware that it can potentially worsen psychosis in vulnerable patients. 1, 2 The major psychiatric guidelines for schizophrenia treatment do not include buspirone as a recommended agent for managing psychotic symptoms. 6